Maria Dobek - 08 Aug 2024 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Vice President, Accounting
Signature
/s/ Maria Dobek
Issuer symbol
JANX
Transactions as of
08 Aug 2024
Net transactions value
$0
Form type
3
Filing time
09 Aug 2024, 19:06:03 UTC
Next filing
03 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Stock option (right to buy) 08 Aug 2024 Common Stock 6,672 $4.21 Direct F1
holding JANX Stock option (right to buy) 08 Aug 2024 Common Stock 4,337 $10.59 Direct F2
holding JANX Stock option (right to buy) 08 Aug 2024 Common Stock 11,989 $20.24 Direct F3
holding JANX Stock option (right to buy) 08 Aug 2024 Common Stock 24,000 $14.02 Direct F4
holding JANX Stock option (right to buy) 08 Aug 2024 Common Stock 26,700 $11.02 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on March 10, 2022 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2 25% of the shares subject to the option vested on May 14, 2022 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3 25% of the shares subject to the option vested on January 1, 2023 and the balance of the shares vest in equal monthly installments thereafter over a three year period.
F4 25% of the shares subject to the option vested on January 1, 2024 and the balance of the shares vest in equal monthly installments thereafter over a three year period.
F5 25% of the shares subject to the option will vest on January 1, 2025 and the balance of the shares will vest in equal monthly installments thereafter over a three year period.